Clinicas Médicas - PUR (28/08) Hepatopatia Crónica y sus complicaciones, Dr. Gaston Nieto

Understanding Hepatic Diseases

Introduction to Hepatic Diseases

• The speaker introduces the topic of hepatic diseases, emphasizing the importance of a broad understanding due to the wide range of potential questions.

• The focus will be on acute and chronic liver diseases, along with miscellaneous topics that may arise in discussions.

Classification of Acute Hepatitis

• Acute hepatitis is classified into three categories: simple, severe, and fulminant.

• Severe hepatitis is characterized by coagulopathy, specifically an INR greater than 1.5 or a prothrombin rate below 50%.

• Fulminant hepatitis includes encephalopathy and significant coagulopathy, often indicated by decreased factor V levels.

Etiological Considerations in Acute Hepatitis

• After classification, determining the etiology is crucial; common causes include viral infections, drug-induced liver injury, autoimmune conditions, and alcohol-related damage.

• Viral hepatitis remains a primary concern; the speaker highlights its frequency and categorizes it based on prevalence.

Focus on Viral Hepatitis

• The discussion shifts to specific viral types: Hepatitis B is noted for causing significant symptoms (90%-95% cases), while Hepatitis C typically presents less acutely.

• The speaker mentions vaccination efforts against Hepatitis A in Uruguay since 2008 but acknowledges ongoing risks due to socioeconomic factors.

Other Systemic Conditions Affecting Liver Health

• Beyond direct viral infections, systemic illnesses like Epstein-Barr virus and cytomegalovirus can also impact liver function.

Hepatotoxicity Mechanisms and Diagnosis

Classic Mechanisms of Hepatotoxicity

• The discussion begins with two classic mechanisms of hepatotoxicity: idiosyncratic reactions and fixed-dose toxicity, particularly highlighting paracetamol's role in acute hepatitis or fulminant liver failure.

• Paracetamol overdose (8g or more) can lead to severe liver damage, especially in patients with pre-existing liver conditions. Predictive factors for idiosyncratic reactions include increasing doses of certain drugs.

• Common drug classes associated with hepatotoxicity include NSAIDs, antibiotics, and antiepileptics. Symptoms typically develop within 100 days of exposure, often involving multiple substances rather than single agents.

Risk Factors and Alternative Therapies

• It is crucial to interrogate patients about the use of herbal products and alternative therapies that may interact with conventional medications, as these also undergo hepatic metabolism.

• Nutritional supplements aimed at weight loss or other purposes can contribute to hepatotoxicity when combined with traditional medications.

Ischemic Hepatitis Insights

• Ischemic hepatitis occurs in patients experiencing shock (cardiogenic or septic), particularly those with rapid arrhythmias like atrial fibrillation.

• A notable pattern is observed where liver enzyme levels drop significantly between the 7th and 10th day post-event, indicating a characteristic response to ischemia.

Autoimmune Hepatitis Markers

• In autoimmune hepatitis cases, high levels of liver enzymes are indicative; normal thresholds range from 200 to 250 U/L but can be much higher during flare-ups.

• Essential diagnostic markers include elevated immunoglobulin G levels during active disease phases and specific antibodies such as anti-smooth muscle antibody (ASMA) and anti-liver kidney microsome type 1 (LKM1).

Histological Confirmation in Autoimmune Cases

• When autoimmune hepatitis is suspected, histological examination remains critical for diagnosis despite any ongoing immunosuppressive treatment; this does not alter histology immediately.

• Key histological features include interface hepatitis, plasma cell infiltration, rosettes formation, and centrilobular necrosis which help confirm the diagnosis.

Distinction Between Autoimmune Conditions

• The speaker emphasizes differentiating autoimmune diseases related to the liver that are not classified as hepatitis but rather cholestatic disorders such as primary biliary cholangitis (PBC).

Overview of Hepatic Conditions and Their Associations

Inflammatory Bowel Disease and Colorectal Neoplasms

• The discussion begins with the association between inflammatory bowel disease (IBD) and colorectal cancer (CC), emphasizing that patients with CC have a higher risk of developing colorectal neoplasms.

IgG4-Related Diseases

• It is noted that primary sclerosing cholangitis is linked to IgG4-related diseases, which include autoimmune pancreatitis type 1. This highlights the importance of recognizing these conditions in clinical practice.

Alcoholic Hepatitis Characteristics

• Alcoholic hepatitis presents similarly to other types of hepatitis but requires specific questioning about alcohol consumption. Key markers include hyperbilirubinemia and renal insufficiency.

Scoring Systems for Alcoholic Hepatitis

• Two scoring systems are introduced:

• The Maddrey score, where a score above 32 indicates severe alcoholic hepatitis, guiding treatment decisions.

• The Lille score assesses response to corticosteroid treatment after seven days.

Wilson's Disease as a Cause of Acute Hepatitis

• Wilson's disease can manifest as acute hepatitis or cirrhosis, typically affecting young patients. Initial symptoms may be neuropsychiatric, followed by hepatic manifestations.

Diagnosis of Wilson's Disease

• Diagnosis involves measuring ceruloplasmin and urinary copper levels. Confusion often arises between Wilson's disease and hemochromatosis; however, only Wilson’s can lead to hepatitis.

Chronic Liver Disease Complications

• Transitioning into chronic liver diseases, it is important to differentiate between compensated and decompensated cirrhosis due to their differing prognoses.

Spontaneous Bacterial Infections in Cirrhotic Patients

• Cirrhotic patients are prone to spontaneous bacterial infections such as spontaneous bacterial peritonitis (SBP), empyema, and bacteremia. These infections complicate their clinical management significantly.

Encephalopathy and Variceal Hemorrhage Risks

• Other complications discussed include portosystemic encephalopathy and variceal hemorrhage, both critical considerations in managing chronic liver disease patients.

Understanding Acute on Chronic Liver Failure

• An introduction to acute on chronic liver failure is provided, although it may not be frequently tested. Recognizing this condition is essential for comprehensive patient care in hepatology.

Importance of Classifying Cirrhosis Stages

Understanding Hepatic Venous Pressure Gradient

The Importance of Hepatic Venous Pressure Gradient

• The hepatic venous pressure gradient (HVPG) is crucial in understanding liver conditions, particularly fibrosis and regeneration nodules that form histologically due to various noxious agents.

• A normal HVPG is up to 5 mmHg; as liver disease progresses, this gradient increases, indicating worsening conditions.

• An HVPG greater than 10 mmHg signifies clinically significant portal hypertension, leading to complications such as varices and ascites.

• An HVPG above 20 mmHg is a strong indicator of variceal hemorrhage risk and mortality associated with liver failure.

Staging of Cirrhosis: Compensated vs. Decompensated

• D'Amico's classification categorizes cirrhotic patients into stages based on their clinical status and HVPG values.

• Stage 1 involves compensated patients without varices or ascites, with an annual mortality rate of only 1%.

• In Stage 2, patients may develop varices that have not yet bled, increasing the mortality rate to approximately 3.4% annually.

• Stage 3 represents decompensated cirrhosis with ascites or prior bleeding episodes, where the mortality rate jumps dramatically to around 20% per year.

Clinical Implications of Ascites

• Ascites can occur in patients without prior liver disease history; differential diagnosis must consider other causes like gastric or ovarian cancer.

• The Gasa index helps determine if ascitic fluid is related to portal hypertension by comparing albumin levels in the fluid versus serum; a value over 1.1 suggests portal hypertension.

Management Strategies for Ascitic Fluid Removal

• Albumin replacement therapy is standard when large volumes of ascitic fluid are drained due to cirrhosis or portal hypertension but not for neoplastic causes.

• When draining more than five liters of ascitic fluid, there’s an increased risk of hemodynamic dysfunction post-paracentesis; thus albumin administration becomes critical at this volume threshold.

Diagnostic Procedures Following Paracentesis

• After paracentesis, it’s essential to analyze the drained fluid for polymorphonuclear leukocyte counts and perform cultures if possible to identify potential infections.

Management of Beta-Blockers in Decompensated Patients

Temporary Suspension of Beta-Blockers

• In recent years, there have been critical windows for the use of beta-blockers, particularly when patients are decompensated. It is essential to consider suspending them temporarily during initial presentations of ascites.

Diagnosis and Treatment of Spontaneous Bacterial Peritonitis (SBP)

• The diagnosis of SBP is straightforward; it involves assessing polymorphonuclear leukocytes (PMNs). A count exceeding 250 PMNs indicates SBP without needing a culture for confirmation.

• The standard empirical treatment for SBP includes administering cefotaxime at 2 grams intravenously every 24 hours for seven days, followed by secondary prophylaxis with norfloxacin on the eighth day.

Identifying Multidrug Resistant Organisms

• Suspicions of multidrug-resistant organisms arise in patients frequently visiting hospitals or undergoing regular procedures like endoscopies. These patients require careful monitoring due to their high exposure to healthcare environments.

Albumin Infusion Protocol

• The second line in treating SBP involves intravenous albumin infusion, which remains unchanged: 1.5 g/kg on the first day and 1 g/kg on the third day.

Complications Related to Ascitic Fluid

Infection Risks from Ascitic Fluid

• Ascitic fluid can become infected or inflamed through bacterial translocation, leading to conditions such as spontaneous bacterial empyema.

Diagnostic Criteria for Empyema

• Diagnosis requires a paracentesis where PMN counts are assessed. An empyema is indicated if PMN counts exceed 500 or if there are positive cultures alongside a count over 250.

Encephalopathy and Its Triggers

Importance of Identifying Precipitating Factors

• In cases of portosystemic encephalopathy, identifying precipitating factors is crucial since infections often underlie these episodes.

Common Causes Leading to Encephalopathy

• Frequent causes include infections and medications that may exacerbate hypotension or contribute to encephalopathic symptoms.

Monitoring Patient Conditions

• Continuous monitoring is vital; clinicians should not wait for overt symptoms like fever but should actively investigate potential underlying issues such as skin infections or urinary tract infections.

Medication Management in Encephalopathy

Review of Medications Contributing to Symptoms

• Various medications can lead to exacerbations in encephalopathy, including diuretics and psychotropic drugs like benzodiazepines that may need suspension during treatment periods.

Addressing Constipation Issues

Understanding Hepatorenal Syndrome and Its Management

Pathophysiology of Hepatic Encephalopathy

• Patients with hepatic encephalopathy may experience episodes due to increased ammonia levels affecting the central nervous system, leading to chronic or recurrent conditions.

Treatment Protocol for Encephalopathy

• In cases of acute encephalopathy, treatment involves administering antibiotics like rifaximin at a high dose (10,000 mg/day), typically using two 200 mg tablets every 8 hours.

Managing Hepatorenal Syndrome

• The management of hepatorenal syndrome requires identifying precipitating factors, particularly focusing on renal insufficiency and potential nephrotoxic medications.

• It is crucial to investigate recent medical interventions such as contrast methods and infections beyond urinary issues, including pneumonia and skin infections.

Assessing Volume Status

• Evaluating the patient's volume status is essential; procedures like paracentesis can lead to complications if not managed properly with adequate albumin replacement.

• Gastrointestinal bleeding, especially from varices, must be suspected in patients presenting with significant drops in hemoglobin or signs of upper gastrointestinal hemorrhage.

Initial Management Steps

• Once precipitating causes are ruled out, initial treatment includes volume expansion therapy using albumin at a dosage of 1 gram per kilogram for 48 hours.

• If no improvement occurs after this period, beta-blockers should be discontinued before starting terlipressin and continuing albumin therapy.

Terlipressin Administration

• Terlipressin acts as a potent vasoconstrictor targeting the splanchnic circulation; it can be administered either as a bolus (1 mg every 6 hours initially) or via continuous infusion.

• Continuous infusion offers lower doses (2 mg in 250 mL over 24 hours), reducing adverse effects compared to bolus administration while maintaining efficacy.

Ongoing Treatment Considerations

• Albumin dosing remains consistent at 1 g/kg during initial treatment phases; thereafter, maintenance doses range from 20 to 40 g daily alongside terlipressin therapy.

Alternative Therapies and Transplantation Options

• If standard treatments fail, alternative therapies such as TIPS (Transjugular Intrahepatic Portosystemic Shunt), MARS (Molecular Adsorbent Recirculating System), or liver transplantation may be considered based on patient eligibility criteria.

Monitoring Renal Function

• Close monitoring of creatinine levels is critical in cirrhotic patients; an increase of more than 0.3 mg/dL within 24 hours indicates acute renal failure requiring immediate attention.

Cirrhosis Management and Hemodynamic Considerations

Inflammatory Response and Hyperdynamic State

• The inflammatory response, along with the renin-angiotensin system, contributes to a hyperdynamic state in cirrhotic patients, perpetuating various complications.

Initial Assessment in Variceal Hemorrhage

• In cases of variceal hemorrhage, the primary focus is on the ABCs (Airway, Breathing, Circulation), ensuring that the patient has not aspirated and managing significant blood loss which can lead to anemia.

Transfusion Guidelines

• A hemoglobin level below 7 g/dL is a clear indication for transfusion; however, between 7 and 9 g/dL requires case-by-case evaluation.

• Indiscriminate transfusions can exacerbate bleeding and portal hypertension; thus, a restrictive approach is recommended.

Nasogastric Tube Placement

• Placing a nasogastric tube in patients with variceal hemorrhage is crucial for management; it does not worsen variceal bleeding due to portal hypertension.

Timeliness of Interventions

• Stabilizing the patient within the first 12 hours post-hemorrhage is critical before any endoscopic interventions are performed.

Use of Terlipressin

• Terlipressin should be administered as soon as possible to manage portal hypertension; initial dosing starts at 2 mg every four hours for two days.

Antibiotic Prophylaxis

• Initiating prophylactic antibiotics like cefotaxime (1g every 24 hours for seven days) is essential to prevent spontaneous bacterial peritonitis during treatment.

Endoscopy Timing

• While endoscopy is necessary for managing varices, it can be scheduled after stabilizing the patient rather than immediately upon arrival.

Balloon Tamponade Techniques

• If bleeding recurs or cannot be controlled via endoscopy, balloon tamponade may be employed but should not exceed 24 hours due to risk of esophageal ischemia.

Stenting Options

• If balloon tamponade fails, an esophageal stent may be placed by a surgeon or gastroenterologist; its duration should not exceed ten days.

Beta-blocker Therapy Post-Hemorrhage

• Propranolol serves as secondary prevention against rebleeding from varices; starting doses are typically low (20 mg every 12 hours), aiming for maximum tolerated doses while monitoring side effects such as erectile dysfunction.

Cardiovascular Risks and Treatment Considerations

Ischemic Heart Disease and Terlipressin

• Patients with untreated ischemic heart disease are at high risk, especially if they have recently undergone procedures like stenting. The use of terlipressin as a vasoconstrictor can lead to ischemia in such cases.

• Critical ischemia, particularly in the inferior region, poses significant risks. While terlipressin is generally safe, each case must be evaluated individually.

Hepatorenal Syndrome and Treatment Protocols

• Terlipressin is validated for use in pump therapy specifically for hepatorenal syndrome but not for variceal gastrointestinal bleeding. Such patients require intermediate care during initial hours.

• Discussions around treatment options often arise in clinical settings; however, there are no major issues reported with current protocols.

Ocreotide vs. Terlipressin

• In scenarios where both ocreotide and terlipressin are available, terlipressin is preferred due to its established efficacy as a vasoconstrictor.

Screening for Hepatocellular Carcinoma

• For cirrhotic patients regardless of etiology, screening for hepatocellular carcinoma involves abdominal ultrasound and alpha-fetoprotein tests every six months.

• A common aphorism states that any nodular liver lesion should be considered hepatocellular carcinoma until proven otherwise through imaging studies.

Imaging Techniques for Diagnosis

• Diagnostic imaging requires three vascular phases: arterial, venous, and portal. This approach helps identify the highly vascularized nature of tumors like hepatocellular carcinoma.

• Accurate imaging can sometimes eliminate the need for histological confirmation via biopsy if characteristic features are present on scans.

Treatment Criteria Overview

• Treatment decisions depend on tumor burden, patient performance status, cirrhosis stage (Child-Pugh classification), and presence of complications like varices or distant metastasis (primarily to lungs or bones).

Acute Chronic Liver Failure Insights

Understanding Acute Chronic Liver Failure

• The concept of acute chronic liver failure is gaining attention; it refers to acute decompensation occurring in patients with pre-existing chronic liver disease.

Patient Decompensation Phenotypes

• Different phenotypes of decompensation correlate with mortality rates; distinguishing between simple decompensations versus those involving multiple organ dysfunction is crucial.

Key Indicators of Severity

• Severe hepatic impairment includes elevated bilirubin levels (>12 mg/dL), significant coagulopathy (INR > 2.5), and renal insufficiency—these factors help classify the severity of acute chronic liver failure using scoring systems like CLIF-SOFA.

Understanding Chronic Liver Diseases and Metabolic Fatty Liver

Diagnosis and Prognosis of Liver Conditions

• The initial step in managing liver diseases is establishing a diagnosis, which significantly influences prognosis. Patients with compensated or decompensated cirrhosis are assessed for six specific conditions to determine their risk of mortality.

• Patients at higher risk are often admitted to intensive care units, and if they meet certain criteria (e.g., age under 65), they may be referred to transplant teams.

Insights on Metabolic Fatty Liver Disease

• Metabolic fatty liver disease has gained attention due to its high prevalence and recent changes in nomenclature; it was previously known as non-alcoholic fatty liver disease.

• The term "metabolic dysfunction-associated steatotic liver disease" (MASLD) was introduced in 2023, reflecting the growing understanding of this condition's association with metabolic disorders.

Diagnostic Criteria for Fatty Liver Disease

• Historically, diagnosing fatty liver required ruling out significant alcohol consumption first. Other less common causes were often overlooked despite the rising obesity epidemic contributing to fatty liver cases.

• Current diagnostic methods include imaging techniques like abdominal ultrasound, which can identify fatty liver alongside assessing cardiometabolic conditions such as diabetes or hypertension.

Risk Assessment and Management Strategies

• Alcohol consumption guidelines indicate that women should limit intake to 140 grams per week and men to 200 grams per week. Coexisting conditions can complicate diagnoses.

• A combination of imaging results and metabolic indicators helps establish a diagnosis of metabolic fatty liver disease. If all tests return negative, further investigation into secondary causes is warranted.

Importance of Fibrosis Assessment

• Fibrosis is identified as the most critical prognostic factor in metabolic fatty liver disease and cirrhosis management.

• The FIB-4 score is a useful tool for evaluating fibrosis risk; low scores suggest minimal fibrosis while higher scores necessitate further evaluation through elastography.

Understanding Portal Hypertension Causes

• Not all portal hypertension arises from cirrhosis; other causes exist including prehepatic factors like thrombosis.

• It’s essential for clinicians to recognize these alternative causes when assessing patients with portal hypertension who do not have cirrhotic backgrounds.

Questions from Participants

• A participant inquires about recommended literature on hepatopathies and clarifies topics covered in residency programs related to chronic hepatitis complications.

Discussion on Family Medicine and Reading Resources

Importance of Reading Materials for Residents

• The speaker emphasizes the necessity of reading classical texts in family medicine, mentioning specific guides and resources that are essential for residents.

• References to European pathology societies highlight the importance of diverse sources in medical education.

• Harrison's principles and Farreras' guidelines are noted as foundational texts for internal medicine residency preparation.

Guidelines for Internal Medicine Residency

• The speaker suggests that these readings serve as a primary guide for residents preparing for their exams, particularly emphasizing the breadth of disciplines involved.

Use of Carvedilol in Digestive Hemorrhage Prevention

Discussion on Preventive Measures

• A question arises regarding the use of carvedilol in primary and secondary prevention of digestive hemorrhage, indicating its relevance in clinical practice.

Patient Scenarios

• The conversation explores scenarios involving compensated cirrhotic patients who may benefit from carvedilol treatment to prevent variceal bleeding.